For example, semaglutide, a second-generation GLP-1 receptor agonist, was approved by the Food and Drug Administration (FDA) in 2021 for the treatment of obesity in adults with a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with body weight-related complications [10]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.